Antibiotic Use Prior to Allogeneic Stem Cell Transplantation May Be Linked to Graft Vs Host Disease
Glycopeptide antibiotic therapy may be linked to risk of extensive chronic graft-versus-host disease after allogeneic stem cell transplantation.
Graft Vs Host Disease
Abatacept May Be Additional Prophylaxis for Graft-vs-Host Disease in Patients With Beta-Thalassemia
Researchers sought to determine whether adding abatacept to standard prophylaxis may reduce rates of GVHD in patients with beta-thalassemia.
Lower Gastrointestinal, Not Upper GI Graft-Versus-Host Disease Increases Healthcare Utilization and Economic Burden for Patients
Researchers have sought to determine the monetary cost of specific aGVHD staging and organ involvement for patients who receive HSCT, a topic which remains poorly understood.
Ruxolitinib Yielded High Response Rate in Children With Refractory GVHD
Ruxolitinib, a selective nonreceptor Janus kinase 1/2 inhibitor shown to have activity in adults with refractory GVHD, was studied in pediatric patients.
Thymoglobulin as GVHD Prophylaxis in AML Conditioning Regimens
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
Abatacept May Help Prevent Severe Acute Graft-vs-Host Disease
A team of investigators sought to determine the ability of abatacept to decrease the risk of severe acute graft-vs-host disease in patients undergoing unrelated donor allogeneic hematopoietic cell transplant.
-
Loading...
-
Loading...
